Salvatore Agnese

Salvatore Agnese

Auto-generated profile, based on publicly available information

Salvatore Agnese

Department of Psychiatry, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Psychiatry Research
Verified
Journal Article
Closed access
FPFrancesco Perris
Francesco Perris
GSGaia Sampogna
Gaia Sampogna
VGVincenzo Giallonardo
Vincenzo Giallonardo
SASalvatore Agnese
Salvatore Agnese
CPCarmela Palummo
Carmela Palummo
FCFrancesco Catapano
Francesco Catapano

27 July 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MFMichele Fabrazzo
Michele Fabrazzo
RZRosa Zampino
Rosa Zampino
MVMartina Vitrone
Martina Vitrone
GSGaia Sampogna
Gaia Sampogna
LGLucia Del Gaudio
Lucia Del Gaudio
Andrea FiorilloAndrea Fiorillo
Andrea Fiorillo
In chronic hepatitis C (CHC) patients, interferon-based treatments showed toxicity, limited efficacy, and psychiatric manifestations. Direct-acting antiviral (DAA) agents appeared safer, though it remains unclear if they may exacerbate or foster mood symptoms in drug-naïve CHC patients. We evaluated 62 CHC patients’ mental status, before and 12 weeks after DAA therapy, by assessment scales and psychometric instruments. We subdivided patients into two groups, CHC patients with (Group A) or without (Group B) a current and/or past psychiatric history. After DAA treatment, Group A patients showed low anxiety and improved depression, no variation in self-report distress, but worse general health perceptions. No significant difference emerged from coping strategies. Depression and anxiety improved in Group B, and no change emerged from total self-reported distress, except for somatization. Moreover, Group B increased problem-focused strategies for suppression of competing activities, and decreased strategies of instrumental social support. Contrarily, Group B reduced significantly emotion-focused strategies, such as acceptance and mental disengagement, and improved vitality, physical and social role functioning. DAA therapy is safe and free of hepatological and psychiatric side effects in CHC patients, regardless of current and/or past psychiatric history. In particular, patients without a psychiatric history also remarkably improved their quality of life.

24 July 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MFMichele Fabrazzo
Michele Fabrazzo
SASalvatore Agnese
Salvatore Agnese
SCSalvatore Cipolla
Salvatore Cipolla
MVMatteo Di Vincenzo
Matteo Di Vincenzo
EMEmiliana Mancuso
Emiliana Mancuso
Mario LucianoMario Luciano
Mario Luciano
Previous studies have indicated that vitamin (Vit) D deficiency is frequent in psychiatric patients, regardless of diagnostic category. We aimed to assess whether acute psychiatric relapses in inpatients was associated with Vit D deficiency compared to stabilized outpatients. The cohort (152 total patients, 75 males and 77 females) had a mean age of 47.3 ± 14.4 years at admission and was grouped according to psychiatric diagnosis. Psychopathological symptom severity was assessed by the Brief Psychiatric Rating Scale (BPRS), a multidimensional symptom inventory. Total calcium serum levels were measured using standard laboratory methods, while plasma levels of 25-OH-Vit D and parathyroid hormone (PTH) were measured by automated chemiluminescence immunoassays. The psychiatric inpatient subgroup showed a significant difference in serum levels of 25-OH-Vit D and PTH (p < 0.001). Correlation analysis between serum levels of 25-OH-Vit D and BPRS total and subitem scores indicated a significantly negative relationship. In addition, linear regression analysis evidenced that the inpatient condition might predict low PTH and 25-OH-Vit D serum levels. Hospitalized psychiatric patients are at increased risk for Vit D deficiency regardless of their diagnostic categories. The mechanism underlying the association between acute psychiatric relapses and Vit D deficiency remains unclear. Therefore, screening for Vit D deficiency should pertain to the health assessment of patients with major psychiatric disorders.

5 July 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
MFMichele Fabrazzo
Michele Fabrazzo
RZRosa Zampino
Rosa Zampino
MVMartina Vitrone
Martina Vitrone
GSGaia Sampogna
Gaia Sampogna
LGLucia Del Gaudio
Lucia Del Gaudio
Andrea FiorilloAndrea Fiorillo
Andrea Fiorillo
In chronic hepatitis C (CHC) patients, interferon-based treatments showed toxicity, limited efficacy, and psychiatric manifestations. Direct-acting antiviral (DAA) agents appeared safer, though it remains unclear if they may exacerbate or foster mood symptoms in drug-naïve CHC patients. We evaluated 62 CHC patients’ mental status, before and 12 weeks after DAA therapy, by assessment scales and psychometric instruments. We subdivided patients into two groups, CHC patients with (Group A) or without (Group B) a current and/or past psychiatric history. After DAA treatment, Group A patients showed low anxiety and improved depression, no variation in self-report distress, but worse general health perceptions. No significant difference emerged from coping strategies. Depression and anxiety improved in Group B, and no change emerged from total self-reported distress, except for somatization. Moreover, Group B increased problem-focused strategies for suppression of competing activities, and decreased strategies of instrumental social support. Contrarily, Group B reduced significantly emotion-focused strategies, such as acceptance and mental disengagement, and improved vitality, physical and social role functioning. DAA therapy is safe and free of hepatological and psychiatric side effects in CHC patients, regardless of current and/or past psychiatric history. In particular, patients without a psychiatric history also remarkably improved their quality of life.